AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03322033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant PS-IDE Stent Graft
Description: Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
Study NCT01498458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib plus capecitabine
Description: Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level.
Study NCT02314975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent vibrational device
Description: Supplementary vibrational force with fixed appliances
Study NCT00783081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-134
Description: K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
Study NCT00783081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 mg BID
Description: Cilostazol 100mg BID for 26 weeks.
Study NCT00783081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 26 weeks.
Study NCT00758589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 50 mg twice daily
Study NCT00758589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 400 mg twice daily
Study NCT00758589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 1000 mg twice daily
Study NCT00758589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00290667 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Study NCT00290667 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Study NCT00290667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00290667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00290667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00290667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00290667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Study NCT03295630 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer
Description: Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
Study NCT04509934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Manipulation
Description: The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
Study NCT02751671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POCUS
Description: The use of Point-of-care ultrasound before urine sample procedure
Study NCT00290667 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT02751671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard
Description: Urine sampling procedure without prior ultrasound
Study NCT03200717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
Study NCT04645745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol, alpha-lactalbumin, folic acid
Description: Evaluating the improvement vs the baseline after three and six months of treatment
Study NCT04631965 — intervention group
Intervention type: BEHAVIORAL
Intervention: Transition support service
Description: The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
Study NCT02314975 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AcceleDent device
Description: Supplementary sham-vibrational device with fixed appliances
Study NCT02314975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliance only
Description: Fixed appliance treatment only
Study NCT03382704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Examination for presence or absence of lanugo hairs
Description: Pre-operative examination for presence or absence of lanugo hairs
Study NCT02648555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily walking
Description: Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
Study NCT02648555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron.
Study NCT00594282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiolucent cushion
Description: MammoPad radiolucent breast plate cushion used during mammogram
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 - Concentrate for solution for infusion
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 800 mg/m2/day - Concentrate for solution for infusion
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day - Concentrate for solution for infusion
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 20 mg/m2/day - Powder for solution for infusion
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3000 mg/m2/day - Powder for solution for infusion
Study NCT02099188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 250 mg/m2/day - Powder for solution for infusion
Study NCT03764618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed.
Study NCT03764618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04597697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
Study NCT02099188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Description: LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
Study NCT02099188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients not needing ENI
Description: 1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
Study NCT02099188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing curative neck irradiation
Description: LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
Study NCT04298424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLSM
Description: The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
Study NCT00031460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
Study NCT00031460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
Study NCT02198794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.
Study NCT02198794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.
Study NCT00852202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cariprazine
Description: Drug: cariprazine (0.25 - 0.75 mg/day)
Study NCT02198794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.
Study NCT02198794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to SD-809 will be administered per schedule specified in the arm.
Study NCT01932255 — intervention group
Intervention type: PROCEDURE
Intervention: prophylactic spinal tap
Study NCT01932255 — intervention group
Intervention type: PROCEDURE
Intervention: no prophylactic spinal tap
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
Study NCT02813304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual reloading
Description: Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
Study NCT02813304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest and cryotherapy
Description: Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
Study NCT03500276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga program
Description: Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
Study NCT00007267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study NCT00007267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease/health education
Study NCT00007267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavioral intervention facilitated by a psychologist
Study NCT01586455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Placental Derived Stem Cell
Description: Infusions of thawed HPDSC to be given following UCB infusion.
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
Study NCT00852202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cariprazine
Description: Drug: cariprazine (1.5 - 3.0 mg/day)
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
Study NCT03891914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using 18F-FCH
Description: Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
Study NCT03891914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using 18F-FDG
Description: Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
Study NCT02226003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 μg, subcutaneous injection, 1 injection per day
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: calcium citrate
Description: 1000 mg of calcium citrate
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium citrate
Description: 1000 mg of calcium citrate
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D
Description: 800 IU of Vitamin D
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 800 IU of Vitamin D
Study NCT03500276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis-education
Description: Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
Study NCT04707599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder plus (telephone call from therapist)
Description: Reminder plus (telephone call from therapist)
Study NCT00852202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules, oral administration, once daily dosing
Study NCT01049854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Intensity with TBI
Description: Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
Study NCT01049854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Intensity
Description: Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
Study NCT01049854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity
Description: Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
Study NCT01049854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity (Fanconi)
Description: Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
Study NCT04070937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular test 1
Description: videonystagmography
Study NCT04070937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular test 2
Description: video head impulse test
Study NCT04070937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular evoked myogenic potentials
Description: vestibular evoked myogenic potentials to measure the function of otolith organs
Study NCT00022113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV